JP2019194190A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194190A5
JP2019194190A5 JP2019102325A JP2019102325A JP2019194190A5 JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5 JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
cancer
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019102325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194190A (ja
JP6794496B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194190A publication Critical patent/JP2019194190A/ja
Publication of JP2019194190A5 publication Critical patent/JP2019194190A5/ja
Priority to JP2020187991A priority Critical patent/JP6985486B2/ja
Application granted granted Critical
Publication of JP6794496B2 publication Critical patent/JP6794496B2/ja
Priority to JP2021191088A priority patent/JP7335310B2/ja
Priority to JP2023133133A priority patent/JP7650923B2/ja
Priority to JP2025038864A priority patent/JP2025102800A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019102325A 2011-10-28 2019-05-31 癌幹細胞特異的分子 Active JP6794496B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020187991A JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011237438 2011-10-28
JP2011237438 2011-10-28
JP2012091142 2012-04-12
JP2012091142 2012-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017228927A Division JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020187991A Division JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子

Publications (3)

Publication Number Publication Date
JP2019194190A JP2019194190A (ja) 2019-11-07
JP2019194190A5 true JP2019194190A5 (https=) 2020-03-12
JP6794496B2 JP6794496B2 (ja) 2020-12-02

Family

ID=48167907

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子
JP2019102325A Active JP6794496B2 (ja) 2011-10-28 2019-05-31 癌幹細胞特異的分子
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Country Status (4)

Country Link
US (3) US20140302511A1 (https=)
EP (2) EP2772268B8 (https=)
JP (7) JP6291254B2 (https=)
WO (1) WO2013062083A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011078301A1 (ja) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
US10247731B2 (en) * 2012-02-22 2019-04-02 Verik Bio, Inc. System for immunotherapy targeting tumor propagation and progression
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
MX2015017852A (es) * 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
CN106537148B (zh) * 2014-06-25 2019-10-11 泰尔哈绍梅尔医学研究基础设施和服务有限公司 癌症干细胞的鉴定及其用于诊断和治疗的用途
KR101779147B1 (ko) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
JP2016028569A (ja) * 2014-07-16 2016-03-03 学校法人慶應義塾 がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、miR−34aの発現量を低下させる方法及びがん幹細胞増殖抑制剤
EP3394107A1 (en) * 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Novel anti-tnfsf9 antibodies and methods of use
JPWO2018181276A1 (ja) 2017-03-28 2020-02-06 学校法人慶應義塾 ヒト組織幹細胞及びその使用
SG11202101297UA (en) * 2018-08-08 2021-03-30 Chugai Pharmaceutical Co Ltd Method for culturing cancer tissue or tissue analogous to cancer tissue
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2427858A1 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1338198B1 (en) 2000-12-01 2007-11-28 Central Institute For Experimental Animals Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
AU2003238897A1 (en) * 2002-06-05 2003-12-22 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1637589A4 (en) 2003-05-16 2007-01-10 Kyowa Hakko Kogyo Kk NEW STEM CELL DERIVED FROM ADULT FABRIC AND THEIR USE
JP2005035943A (ja) 2003-07-16 2005-02-10 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制剤
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
CA2542121A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Genomically modified cell neutralized to serum-free system
JP2005206508A (ja) * 2004-01-22 2005-08-04 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制抗体
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2005111076A1 (en) * 2004-05-12 2005-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) as a marker for cancer prognosis
US7498315B2 (en) 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2006039678A2 (en) 2004-09-29 2006-04-13 Central Institue For Experimental Animals Establishment of highly metastatic cell lines using nog mice
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
EP1815864A4 (en) 2004-11-15 2009-08-05 Kyowa Hakko Kirin Co Ltd METHOD FOR THE SUPPRESSION OF METASTASIS OF CANCER CELLS AND MEDICAL COMPOSITION THEREFOR
CN101203241B (zh) * 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20090012024A1 (en) 2005-07-26 2009-01-08 Procure Therapeutics Limited Stem Cell Markers
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
EP1792979A1 (en) 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
EP1971371B1 (en) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
WO2007124125A2 (en) * 2006-04-21 2007-11-01 Stowers Institute For Medical Research Methods of identifying stem cells in normal and cancerous tissues and related progeny cells
JPWO2007132883A1 (ja) 2006-05-17 2009-09-24 公立大学法人横浜市立大学 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット
EP2032694A4 (en) 2006-06-06 2010-09-15 Univ Tennessee Res Foundation COMPOSITIONS ENRICHED WITH NEOPLASTIC STEM CELLS AND THESE COMPREHENSIVE METHODS
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
JP5286265B2 (ja) 2006-08-11 2013-09-11 アーオー−フォルシュングスインスティチュート ダボス 均一な幹細胞群を取得するための特定種類へ分化させるのにかかわる幹細胞の識別及び選択
MX2009002418A (es) * 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
EP2076587A4 (en) 2006-09-11 2009-12-09 Univ Florida ISOLATION, EXPANSION AND USE OF TUMOR STAMMING CELLS
GB2442059A (en) 2006-09-19 2008-03-26 Ist Superiore Sanita Test for cancer of the gastrointestinal tract
MY162056A (en) * 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
JP2008102012A (ja) 2006-10-19 2008-05-01 Kanazawa Univ 癌幹細胞の同定および単離方法
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포
JP2008182912A (ja) 2007-01-29 2008-08-14 Nippon Kayaku Co Ltd 癌幹細胞の培養方法、および癌幹細胞
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2008149803A1 (ja) 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
US20110244502A1 (en) 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
CA2700457A1 (en) 2007-10-01 2009-04-09 Austin Smith Neural tumor stem cells and methods of use thereof
WO2009064301A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
SG186660A1 (en) 2007-12-14 2013-01-30 Chugai Pharmaceutical Co Ltd Novel method for specimen preparation, which ensures preservation of tissue morphology and nucleic acid quality
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
US8163551B2 (en) * 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010009121A2 (en) 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
AU2010221159B2 (en) * 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
CA2757114C (en) * 2009-03-30 2019-05-21 Universite De Lausanne Preparation of isolated agonist anti-edar monoclonal antibodies
WO2010123891A1 (en) * 2009-04-20 2010-10-28 Genentech, Inc. Adjuvant cancer therapy
TW201105347A (en) * 2009-04-28 2011-02-16 Chugai Pharmaceutical Co Ltd Pharmaceutical compositions for maintenance therapy containing HLA class I-recognizing antibody as the active ingredient
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011078301A1 (ja) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
WO2012096545A2 (ko) * 2011-01-13 2012-07-19 연세대학교 산학협력단 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US10504315B2 (en) 2013-08-05 2019-12-10 Ncr Corporation Clamping of media items

Similar Documents

Publication Publication Date Title
JP2019194190A5 (https=)
JP6603685B2 (ja) クロストリジウム・ディフィシレの主要な外毒素TcdA及びTcdBに対する中和抗体
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
JP2019527706A5 (https=)
JP2009539380A5 (https=)
TW201427664A (zh) Tec家族激酶抑制劑佐劑療法
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
HRP20151261T1 (hr) Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2018523686A5 (https=)
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
CN111372606A (zh) 增强atp释放作用
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
JP2017113019A5 (https=)
CN110698558B (zh) 一种tpbg抗体及其制备方法、其偶联物和应用
Raeisi et al. Application of recombinant antibodies for treatment of Clostridioides difficile infection: current status and future perspective
WO2014151606A4 (en) Methods of treating pancreatic cancer
JP2014223083A5 (https=)
CN110114087A (zh) β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途
CN111278992A (zh) 用抗egfr抗体治疗癌症的组合物和方法
EP4243827A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR20200143385A (ko) Mospd2와, t 세포 또는 nk 세포 특이적 분자에 대한 2중 특이적 항체
CN109071659B (zh) 人抗fgfr4抗体和索拉非尼的组合
JP2018536026A (ja) ErbB3に特異的に結合する抗体、及びその用途